Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Sleep-Wake Disturbances In Mild Traumatic Brain Injury: Meta Analysis Of Literature And Modeling Of Cerebral Tissue Vulnerability, Xiangfu Zhang, Subhendra Sarkar, Mary A. Browne
Sleep-Wake Disturbances In Mild Traumatic Brain Injury: Meta Analysis Of Literature And Modeling Of Cerebral Tissue Vulnerability, Xiangfu Zhang, Subhendra Sarkar, Mary A. Browne
Publications and Research
Sleep disturbance is a frequent complaint for patients with mild traumatic brain injury (mTBI), it can prolong recovery, and the oxidative stress from lack of sleep could worsen other secondary damages of mTBI. The common types of sleep disturbance of mTBI include insomnia, daytime sleepiness, and obstructive sleep apnea. Conventional imaging often fails to detect any abnormalities in mTBI, and the etiology of sleep disturbance is still unclear. Based on the analysis of current published neurobiological and imaging literature, multiple factors could play a role leading to sleep disturbance in mTBI, however, we have focused on the diencephalon, melatonin and …
Peripheral Blood Clinical Laboratory Variables Associated With Outcomes Following Combination Nivolumab And Ipilimumab Immunotherapy In Melanoma, Samuel Rosner, Erica Kwong, Alexander N. Shoushtari, Claire F. Friedman, Allison S. Betof, Mary Sue Brady, Daniel G. Coit, Margaret K. Callahan, Jedd D. Wolchok, Paul B. Chapman, Katherine S. Panageas, Michael A. Postow
Peripheral Blood Clinical Laboratory Variables Associated With Outcomes Following Combination Nivolumab And Ipilimumab Immunotherapy In Melanoma, Samuel Rosner, Erica Kwong, Alexander N. Shoushtari, Claire F. Friedman, Allison S. Betof, Mary Sue Brady, Daniel G. Coit, Margaret K. Callahan, Jedd D. Wolchok, Paul B. Chapman, Katherine S. Panageas, Michael A. Postow
Publications and Research
Both the combination of nivolumab + ipilimumab and single-agent anti-PD- 1 immunotherapy have demonstrated survival benefit for patients with advanced melanoma. As the combination has a high rate of serious side effects, further analyses in randomized trials of combination versus anti-PD- 1 immunotherapy are needed to understand who benefits most from the combination. Clinical laboratory values that were routinely collected in randomized studies may provide information on the relative benefit of combination immunotherapy. To prioritize which clinical laboratory factors to ultimately explore in these randomized studies, we performed a single-center, retrospective analysis of patients with advanced melanoma who received nivolumab …